About Ocuphire
Ocuphire is a company based in West Bloomfield Township (United States) founded in 2018. Ocuphire has raised $6.77 million across 3 funding rounds from investors including Raiffeisen Bank International, Grand Angels and First Capital Fund. The company has 8 employees. Ocuphire has completed 1 acquisition, including Opus Genetics. Ocuphire offers products and services including Gene Therapy Pipeline, IRD Programs, and Partnered Programs. Ocuphire operates in a competitive market with competitors including Annexon, Aldeyra, Nicox, Gyroscope and MeiraGTx, among others.
- Headquarter West Bloomfield Township, United States
- Employees 8
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website ocuphire.com
- Social LinkedIn X
- Legal Name Ocuphire Pharma, Inc.
- Annual Revenue$19.05 M (USD)-52as on Dec 31, 2023
- Net Profit-$9.99 M (USD)-156as on Dec 31, 2023
- EBITDA-$10.56 M (USD)-158as on Dec 31, 2023
- Total Equity Funding$6.77M (USD)
in 3 rounds
- Latest Funding Round$5M (USD), Series A
Jul 2019
- InvestorsRaiffeisen Bank International
& 8 more
- Employee Count8
- Investments & Acquisitions
Products & Services of Ocuphire
Ocuphire offers a comprehensive portfolio of products and services, including Gene Therapy Pipeline, IRD Programs, and Partnered Programs.
Develops gene therapies targeting mutations in retinal disease genes.
Focuses on therapies for inherited retinal diseases like LCA and RP.
Advances gene therapies through partnerships for retinal disorders.
Funding Insights of Ocuphire
Ocuphire has successfully raised a total of $6.77M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $5 million completed in July 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $6.77M
- Total Rounds 3
- Last Round Series A — $5M
- Investors Count 9
All 3 funding rounds of Ocuphire with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2019 | $5M | Series A | – | Raiffeisen Bank International, Grand Angels | – |
| May 2018 | – | Debt – Conventional | – | – | – |
| May 2018 | $1.77M | Seed | – | – | – |
9 investors in total: 9 institutional.
Investors in Ocuphire
Ocuphire has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Raiffeisen Bank International, Grand Angels and First Capital Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Grand Angels is engaged in angel investing for startups. | 2005 | grandangels.org | Grand Rapids, United States | |
- | – | firstcapital-fund.com | - | |
Early-stage company funding is facilitated in Michigan. | – | miangelfund.com | Ann Arbor, United States | |
Funding is provided for Michigan-based life sciences ventures. | 2003 | wmubrcc.com | Kalamazoo, United States | |
Blue Water Investors is recognized as a premier buyers agency in Australia. | – | bluewaterangels.com | Australia | |
Early stage investment capital is provided by Woodward Angels. | – | woodwardangels.com | Grand Rapids, United States | |
Investment in women-led companies is facilitated for superior returns. | 2018 | bellefunds.com | - | |
Investment banking operations are conducted across multiple sectors. | 1996 | rbinternational.com | Vienna, Austria | |
- | – | annarborangels.com | - |
Investor details for Ocuphire
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Ocuphire
37 people are tracked at Ocuphire (7 in leadership, 26 in board & advisors, 4 in team); the tracked headcount is 8.
| Name | Role | Group |
|---|---|---|
Bindu Manne | Head of Market Development & Commercialization | Leadership |
Mitchell Brigell | Head of Clinical Development & Strategy | Leadership |
Drey Coleman | VP, Clinical Operations | Leadership |
Richard Rodgers | Interim CEO | Leadership |
Chris Ernst | Global Head, QA & Manufacturing | Leadership |
Laura Gambino | Director of Project Management | Leadership |
Joe Schachle | Chief Operating Officer | Leadership |
Inder Paul Singh | Medical Advisor | Board & advisors |
Justin Schweitzer | Medical Advisor | Board & advisors |
Y. Ralph Chu | Medical Advisor | Board & advisors |
Cam Gallagher | Chairman Of The Board Of Directors | Board & advisors |
Eliot Lazar | Medical Advisor | Board & advisors |
Paul Karpecki | Medical Advisor | Board & advisors |
David S. Boyer | Medical Advisor | Board & advisors |
Selina McGee | Medical Advisor | Board & advisors |
Susan Benton | Director | Board & advisors |
Sean Ainsworth | Director | Board & advisors |
Jay Pepose | Director | Board & advisors |
Marguerite McDonald | Medical Advisor | Board & advisors |
Thomas W. Samuelson | Medical Advisor | Board & advisors |
17 more people are available in the full profile.
Complete people profiles for Ocuphire
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ocuphire
Ocuphire has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Opus Genetics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Gene therapies for retinal degenerative diseases are developed. | opusgtx.com | Durham, United States | 2021 | Oct 2024 | •••• |
Complete acquisition details for Ocuphire
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Ocuphire
4 dated milestones of Ocuphire across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Ocuphire is founded.
- Funding First funding round.
- Funding Latest funding round, Series A, of $5.0M.
- Acquisition Acquires Opus Genetics.
Competitors of Ocuphire
Ocuphire operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Annexon, Aldeyra, Nicox, Gyroscope and MeiraGTx, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| aldeyra.com | 2004 | Lexington, United States | $4.79M | 30 | Drug candidates for immune-mediated diseases are developed by Aldeyra. | |
| nicox.com | 1996 | Valbonne, France | $271.01M | – | Nitric oxide-based therapeutics for glaucoma and eye conditions are developed. | |
| gyroscope.cc | 2016 | San Francisco, United States | – | – | Mobile SDK developed for app engagement and monetization strategies. | |
| meiragtx.com | 2015 | New York, United States | – | 358 | Gene therapies for ocular and neurodegenerative diseases are developed. | |
| gensight-biologics.com | 2011 | Paris, France | $76.63M | – | Viral vector-based gene therapies for retinal diseases are developed. | |
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| alimerasciences.com | 2003 | Alpharetta, United States | $66.8M | 79 | Ophthalmic pharmaceuticals for diabetic macular edema are developed and commercialized. | |
| perceivebio.com | 2021 | San Francisco, United States | $78M | – | Developer of therapeutics to treat diabetes and eye diseases | |
| adverum.com | 2006 | Menlo Park, United States | $131.43M | 123 | Gene therapies for ocular disorders are developed. |
Detailed competitors of Ocuphire
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ocuphire
Complete news archive for Ocuphire
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Ocuphire
10 companies that operate in the same segment as Ocuphire (Ophthalmology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 | |
Ophthalmic pharmaceuticals for diabetic macular edema are developed and commercialized. | 2003 | Alpharetta, Georgia, United States | USD 66.8 M | USD 80.75 M | 79 | |
AI-powered portable solutions for ophthalmic screening and diagnosis are developed. | 2009 | Bengaluru, Karnataka, India | USD 25.01 M | USD 4.85 M | 135 | |
Gene therapies for ocular and neurodegenerative diseases are developed. | 2015 | New York, New York, United States | – | USD 81.39 M | 381 | |
Small molecule therapeutics for ophthalmic disorders are developed. | 1987 | Watertown, United States | – | USD 31.37 M | 165 | |
Therapies for metabolic and orphan diseases are developed by Rezolute. | 2012 | Denver, Colorado, United States | – | – | 59 | |
Manufacturer of portable digital eye imaging devices and cloud-based healthcare platforms | 2010 | Bengaluru, Karnataka, India | USD 18.12 M | USD 4.78 M | 145 | |
Therapeutics for retinal diseases are developed by the company. | 2009 | Palo Alto, California, United States | USD 35.84 M | – | 109 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Ocuphire
Ocuphire was founded in 2018.
Ocuphire is headquartered in West Bloomfield Township, United States. It is registered at West Bloomfield Township, Michigan, United States.
Ocuphire is a funded company, having raised a total of $6.77M across 3 funding rounds to date.
Ocuphire has 8 employees.
Annual revenue of Ocuphire is $19.05M as on Dec 31, 2023.
Developer of therapeutics for the treatment of refractive and retinal eye disorders. Its lead product, Nyxol is a once-daily eye drop for vision disturbances, glaucoma, and presbyopia. Its product MIRA-2 is a reversal of mydriasis phase 3 clinical trial for Nyxol, LYNX-1 is in phase 3 and VEGA-1 is in presbyopia phase 2 clinical trial for Nyxol with low-dose pilocarpine.
Ocuphire's top competitors include Annexon, Alimera Sciences and MeiraGTx.
Ocuphire offers Gene Therapy Pipeline, IRD Programs, and Partnered Programs.
Ocuphire has made 1 acquisition, including Opus Genetics.
Ocuphire has 9 investors. Key investors include Raiffeisen Bank International, Grand Angels, First Capital Fund, Ann Arbor Angels, and Michigan Angel Fund.
Ocuphire operates through Ocuphire Pharma, Inc..